The Case for Clinical Expertise in MSK and Cardiovascular Care
AHIP MMDC26 · Specialty Care Panel Recap
Published by TurningPoint Healthcare Solutions
Specialty care is consuming an ever-larger share of health plan budgets — and delivering inconsistent clinical outcomes in return. At AHIP MMDC26, three chief medical officers sat down to talk about why, and what serious management of MSK and cardiovascular services actually requires. The conversation kept returning to a single theme: the gap between the complexity of these cases and the clinical depth of the systems built to manage them.
The panelists were Dr. David Halsey, Chief Clinical Officer at TurningPoint Healthcare Solutions; Dr. David Williams, CMO and Executive Vice President at CareSource; and Dr. David Granger, Market Chief Medical Officer at AmeriHealth Caritas D.C. The session was moderated by Lydia Turner of PwC's Health Transformation Practice.
1. Specialty care is 25–33% of the spend — and 20–30% of it may be inappropriate
Dr. David Granger set the stakes early. As a steward of government dollars across 13 Medicaid states, AmeriHealth Caritas cannot move the needle on cost and quality without confronting specialty care directly. The numbers are too large and the variation too significant to treat it as a secondary priority.
Dr. David Williams widened the lens from CareSource's position across 14 states, operating entirely within government-sponsored programs. The challenge has shifted from managing trend lines to managing entire financial funding models. Gene and cell therapies, high-cost biologics, and rapidly evolving oncology and cardiovascular protocols are pushing individual treatment costs past a million dollars per member in some cases. The science, Williams argued plainly, has outpaced the financial frameworks health plans were built around.
The variation problem in MSK and cardiovascular care sits at the center of this. It shows up in surgical rates, device and implant selection, site of service, appropriateness of indication, and surgical assistance decisions. It is simultaneously a quality problem and a cost problem — and for health plans carrying full risk, the two cannot be separated.
2. Medical knowledge is doubling every 73 days. The generalist model for UM can't keep pace.
Dr. David Williams offered the session's most striking data point: in 1950, medical knowledge doubled every 50 years. By 1980, every seven years. By 2010, every 3.7 years. Today: every 73 days.
"You need someone who lives in that specialty care space every day." - Dr. David Williams, CMO & EVP, CareSource
The implication for utilization management is direct and uncomfortable. A UM program built on primary care reviewers was designed for an era when the scope of review was narrower and the clinical questions more general. Applying that model to complex spine reconstructions, structural heart procedures, or high-cost biologics creates a mismatch between the reviewer and the case that health plans and their members absorb the consequences of.
Dr. David Granger reinforced the point from the provider side: when the reviewer has actually performed the procedure being requested, the peer-to-peer conversation is categorically different. The clinical credibility changes the dynamic. The trust changes. And ultimately the outcome changes.
3. Prior authorization was invented as a clinical conversation. It needs to function like one again.
The panel traced a history the industry knows but rarely examines critically. UM was created in the 1960s as a peer discussion between clinicians. By the end of the 1980s it had expanded from touching 5% of members to 80%. Today it is a near-universal experience in American healthcare — and the original clinical intent has been largely displaced by administrative volume.
Dr. David Halsey described what restoring that intent requires: moving away from broad, primary-care-based policies applied at scale, toward subspecialty-specific review concentrated on the cases where clinical expertise at the point of decision changes the outcome.
"TurningPoint exists to bring back the clinical impact of prior authorization — to give every patient access to a genuine subspecialty review, by the right expert, at the moment that matters most for their care." Dr. David Halsey, Chief Clinical Officer, TurningPoint Healthcare Solutions
Dr. David Granger named the failure modes health plans deal with daily in legacy UM: lag time, treatment delays, provider frustration, and decisions made without complete clinical information. The answer, the panel agreed, is not more administrative process. It is better clinical information captured earlier, reviewed by clinicians with the right subspecialty depth to act on it.
4. The real opportunity is upstream and downstream of the authorization
Dr. David Williams outlined three levers available to health plans managing specialty cost: utilization management, contracting with transparent data sharing, and predictive care coordination that engages members before they reach high-cost intervention points. Of these, he argued, the third is the most underutilized. If a plan can identify a rising creatinine trend in its data, waiting for the member to arrive at an end-stage procedure is not a management strategy.
On the provider side, Dr. David Halsey reframed what effective UM engagement actually looks like.
"If you want to change behavior, you have to bring trust. When a spine surgeon needs a peer review, they should be talking to another spine surgeon — not a generalist. That's the opportunity we've underutilized in this country, and it's exactly why TurningPoint exists." Dr. David Halsey, Chief Clinical Officer, TurningPoint Healthcare Solutions
Providers in MSK and cardiovascular care are operating under significant pressure, often without complete information, and frequently siloed from the clinical evidence that should be shaping their decisions. A subspecialist peer in the conversation — armed with current evidence, transparent policies, and national specialty society guidelines — changes that dynamic in a way that a generalist reviewer simply cannot. It is also how health plans build the provider relationships that value-based arrangements ultimately depend on.
5. Equitable access to subspecialty care is a utilization management problem
This was the session's most underappreciated point, and Dr. David Halsey raised it directly.
"In a metro area you may have access to nine different shoulder specialists within five days. But if you're in middle America, you're limited to a single voice, maybe 100 miles away. Bringing subspecialty expertise to prior authorization is how we lift the entire market." Dr. David Halsey, Chief Clinical Officer, TurningPoint Healthcare Solutions
The access gap in specialty care is as geographic as it is financial. A member in a major urban market has options — multiple specialists, second opinions, competing clinical perspectives. A member in rural Tennessee may have one orthopedic surgeon within a reasonable drive. The quality of the clinical review they receive in the prior authorization process should not compound that inequity. Bringing genuine subspecialty depth to UM is one of the few mechanisms available to health plans that addresses this regardless of where the member lives.
Dr. David Williams connected this to CareSource's founding identity — started by a social worker 37 years ago to address the non-medical drivers of health, with health equity built into its clinical model from the beginning, from social determinants analytics to community health worker certification programs developed with local university partners.
Dr. David Granger framed it operationally: even in a dense market like Washington D.C., timely access to the right level of care remains a persistent challenge. When members cannot access primary care when they need it, they present at higher-acuity settings inappropriately. Access, equity, and utilization are not separate problems. They are expressions of the same one.
The through-line
Three chief medical officers — from a Medicaid-focused health plan, a multistate government program plan, and a specialty condition management company — with different markets, different member populations, and different stages of value-based maturity. Consistent alignment on what the MSK and cardiovascular management problem actually requires.
The volume-based, generalist-reviewed model of utilization management was not built for a world where medical knowledge doubles every 73 days, where a single biologic can exceed a million dollars, and where the variation in these two specialties represents both the largest clinical quality gap and the most significant unmanaged cost exposure for health plans carrying full risk. Closing that gap requires subspecialty depth at the point of review, earlier engagement with members and providers, and a willingness to be accountable for the outcomes that follow.
That was the conversation at AHIP MMDC26. It is one the industry needs to keep having.
TurningPoint Healthcare Solutions provides subspecialty-specific clinical and technology-enabled condition management for musculoskeletal and cardiovascular services. TurningPoint is an independent organization, not affiliated with any health plan or provider system.
